At least 50,000 volunteers are needed to participate in clinical trials for Alzheimer’s disease – the global cost of which is expected to reach $2 trillion by 2030.
In an exclusive licensing agreement with Merck & Co Inc (MSD), Cerveau will take on development of the firm’s investigative PET imaging agent up to Phase III trials for Alzheimer’s Disease.
A transdermal patch formulation of the most commonly used Alzheimer's disease (AD) drug could be on the market in 2019 - two to three years earlier than expected.
Merz is hoping to further its Alzheimer’s research by licensing DiaGenic’s biomarkers for a transitional stage of disease, which is “very important” for stratification of clinical trials.
Peptide Technologies showcased their latest rapid automated peptide
synthesis equipment at Pittcon 2008, including a new product, the
benchtop Tribute instrument.
Scientists have discovered that a protein called cystatin C can
prevent damaging Alzheimer's plaques from forming by keeping their
constituent protein water soluble.
The UK's largest charity, the Wellcome Trust, has awarded £1.3m
(€1.9m) to fund the world's largest ever genome-wide association
study to identify the genetic origins of Alzheimer's disease.
UK researchers have published results linking the beta amyloid
protein associated with Alzheimer's disease to glaucoma, opening up
a much needed new target for glaucoma therapies.
US-based researchers have developed a transdermal vaccine for
Alzheimers disease which has been shown to clear brain-damaging
amyloid plaques in preclinical studies, offering hope to millions
of sufferers worldwide.
A federal scientist has been charged with criminal conflict of
interest after he allegedly performed consultancy work that
improperly overlapped with government work.
US drug developer Samaritan Pharmaceuticals has filed a patent for
a new drug that could treat a wide range of neurodegenerative
disorders, including Alzheimer's disease, by clearing out amyloid
plaques in the brain.
Scientists have uncovered a naturally occurring enzyme that can
break down a component of the brain plaques that play a central
role in Alzheimer's disease, which could provide researchers with a
basis for new therapies to treat...
Pfizer has revealed details of its new agreement with Transtech
Pharma in which the two companies will focus on the receptor for
advanced glycation end products (RAGE) with potential for use in
treating Alzheimer's disease.
Patients suffering from Alzheimer's disease are one step closer to
receiving Novartis's Exelon as a transdermal patch instead of a
capsule following an international clinical study which showed that
the new delivery method...
Neuropharma has developed a new treatment for Alzheimer's Disease,
which uses a unique method of attack, incorporating a mechanism of
action that targets a little-known enzyme that contributes to the
proliferation of the neurodegenerative...
New drugs that are based on a compound found in the body may give
renewed hope to stroke victims and sufferers of degenerative brain
diseases such as Alzheimer's as researchers are hopeful of a new
therapeutic approach.
The world's first transdermal patch for the treatment of
Alzheimer's disease (AD) will offer patients an improved treatment
delivery choice and could lead to more patients taking their
medication.
Researchers believe that they have identified a drug target
molecule that could be used to treat mental impairment in people
with Down's syndrome paving the way for a treatment that could
improve the quality of life for sufferers.
A Phase I clinical trial, which is investigating the
pharmacological activities of a compound for the treatment of
Alzheimer's disease, has just been completed with results
indicating improved efficacy and pharmacokinetics over...
A clinical trial will shortly get underway to see if insulin,
delivered intranasally using an atomiser developed by Kurve
Technology, can improve short-term memory in Alzheimer's disease
patients.
Scientists from the University of California have discovered three
molecules that show great potential in the development of new
Alzheimer's drugs. The new therapy targets a protein that
accumulates in Alzheimer's victims...
A handful of Alzheimer’s drug treatments and lifestyle-based
interventions shared the spotlight at the first ever Alzheimer’s
Association Prevention conference, in which scientists worldwide
took the opportunity to showcase the latest...
Significant progress toward a more targeted treatment of
Alzheimer's disease was made as scientists targeted an enzyme,
which has a differentiated role and opens up perspectives for new
drugs that have fewer undesired side effects.
Scientists have identified a new, longer species of the amyloid
b-peptide that has the potential to be a new target for the
treatment of Alzheimer's disease The discovery serves as a basis
for treating one of the characteristic...
Researchers have identified a protein that protects the brain from
the destructive effects of Alzheimer's disease, protecting brain
cells by blocking another toxic protein that contributes to the
disease process
Regen Therapeutics (ReGen) announced it had entered into an
agreement to acquire Guildford Clinical Pharmacology Unit Limited
(GCPUL) confirming its strategy to develop its medical service
revenue generating business and developing...
A report that focuses on Alzheimer's Disease and the crop of new
drugs to treat it, cites neuroprotection as a potential treatment
that may become more effective than the host of symptomatic
treatments currently available.
The results of an ongoing study could revolutionise Alzheimer's
disease treatment as a new technique, which uses a gene therapy
agent to deliver a drug containing nerve growth factor (NGF), to
the brain area affected by Alzheimer's...
A study, which uses immunoglobulins to treat multiple sclerosis,
may also be able to help patients with Alzheimer's. The discovery
seems to point towards an approach, which treats Alzheimer's with
anti-bodies, which are...
Celera Diagnostics announced it has entered into a collaboration
with Merck to identify novel targets for drug discovery and
diagnostic markers related to Alzheimer's disease.
The first clinical trial of a peptide that mimics the cellular
adhesion molecule NCAM is due to take place in the UK in the third
quarter of this year, bringing a potential new treatment for
Alzheimer's disease a step closer,...
The enzyme alpha secretase could join its beta and gamma cousins as
a promising new target for Alzheimer's disease drugs, if research
conducted in Germany is borne out in additional study.
Researchers in France and the US have used a technique known as
click chemistry to discover potent new inhibitors of
acetylcholinesterase, an enzyme that serves as a drug target in
Alzheimer's disease, writes Phil Taylor.
De Novo Pharmaceuticals says it has refocused its business from
in-house drug discovery to commercialisation of its proprietary
in silico drug discovery platforms, halving its workforce in
the process.
Scientists at Berlex Pharmaceuticals, the US subsidiary of
Germany's Schering, have identified a biologic marker for
Alzheimer's that could form the basis of a diagnostic test.
Aventis has licensed a drug for Alzheimer's disease and other forms
of dementia from Japan's Dainippon; AC-3933 is claimed to have a
completely novel mechanism of action.
Researchers have uncovered evidence that the first time that
neurotoxic peptide assemblies known as ADDLs are responsible for
Alzheimer's disease in humans.
Japanese drugmaker Eisai is planning to double the production
capacity for its two top-selling drugs - Pariet and Aricept - by
2004, with an investment of ¥9 billion (€65m).
